FDA approves Voraxaze from BTG for ultra-rare indication
This article was originally published in Scrip
Executive Summary
The US FDA has granted approval for BTG's biologics license application for Voraxaze (glucarpidase) to treat high dose methotrexate toxicity, an ultra-rare indication with only 300 sufferers in the US per year.